Table 3.

Effect modifications of treatment on the association between 48-months changes in each heart fat depot and 48-months changes in CIMT

	48-months Δ CIMT
	48-months Δ EAT		48-months Δ PAT
	β (95% CI)	P-valuea	β (95% CI)	P-valuea
	Model 1
Per 1 SD increase in 48-months Δ heart fatb
o-CEE	------	-----	-----	-----
t-E2	7.23 (−3.03,17.48)	0.17	14.28 (3.67,24.90)	0.009
Placebo	5.01 (−4.14,14.17)	0.28	12.11 (3.06,21.16)	0.009
P-value for interaction
48-months Δ heart fat depot * treatment group	0.34		0.009
	Model 2
Per 1 SD increase in 48-months Δ heart fatb
o-CEE	-----	-----	-----	-----
t-E2	6.77 (−3.67,17.20)	0.20	12.54 (1.75,23.34)	0.02
Placebo	4.61 (−4.75,13.97)	0.33	10.00 (0.75,19.25)	0.03
P-value for interaction
48-months Δ heart fat depot * treatment group	0.41		0.04
	Model 3
Per 1 SD increase in 48-months Δ heart fatb
o-CEE	----	-----	----	-----
t-E2	6.83 (−3.62,17.29)	0.20	12.66 (1.80, 23.52)	0.02
Placebo	4.64 (−4.73,14.02)	0.33	10.09 (0.79, 19.39)	0.03
P-value for interaction
48-months Δ heart fat depot * treatment group	0.40		0.04

^aP value of each treatment group compared to o-CEE

^bEstimates per 1 SD increase in heart fat depot change (SD for EAT change=15.47; for PAT change=7.79)

Model 1. Unadjusted

Model 2. includes age, race (white v/s non-white), location of study site (east, west and middle), employment, LDL-C, BMI, alcohol, smoking, systolic blood pressure, diastolic blood pressure, anti-hypertensive medication, log-triglycerides, log-HOMA, log-C-reactive protein, log-Leptin, log-high molecular weight adiponectin

Mode 3. Model 2 plus log transformed baseline heart fat depot volume as appropriate